RASP (Actavia Life Sciences) Total Debt per Share: $0.00 (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Actavia Life Sciences Total Debt per Share?

Actavia Life Sciences RASP -87.50% Total Debt per Share is $0.00 as of Mar. 2024.

$0.00 (As of Mar. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Actavia Life Sciences's Total Debt Per Share for the quarter that ended in Mar. 2024 was $0.00.

Actavia Life Sciences Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Total Debt per Share Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 0.01 0.00 0.00

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Actavia Life Sciences Total Debt per Share Calculation

Actavia Life Sciences's Total Debt Per Share for the fiscal year that ended in Sep. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.21)/771.81
=0.00

Actavia Life Sciences's Total Debt Per Share for the quarter that ended in Mar. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.30)/771.81
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.00 mean?
Actavia Life Sciences (RASP) has a Total Debt per Share of $0.00 as of Mar. 2024. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Total Debt per Share too high?
Actavia Life Sciences' current Total Debt per Share is $0.00.
How does Actavia Life Sciences' Total Debt per Share compare to BWV and FNCH?
Actavia Life Sciences' Total Debt per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Total Debt per Share of $0.00. The current Total Debt per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Total Debt per Share is $0.00 as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.